pharma news today glp-1 obesity drugs today Weight loss with medicines does not result in a disproportionate loss of muscle mass or function in obese mice and humans: Cell Reports Medicine The GLP-1 Revolution: How Next-Generation
Description
2021;106(2):E592-601
In rodent models of vascular injury, exenatide demonstrated its potential to reduce restenosis risk post-angioplasty by minimizing neointimal hyperplasia [38]
Demonstrate long-term ROI to plan sponsors
Psychiatric adverse events associated with semaglutide, liraglutide and tirzepatide: a pharmacovigilance analysis of individual case safety reports submitted to the EudraVigilance database
Aston-Mourney K, Subramanian SL, Zraika S, Samarasekera T, Meier DT, Goldstein LC, and Hull RL
